Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

RAP-ALS investigators group; RAP-ALS Investigators group; J. Mandrioli; R.  D'Amico; E. Zucchi; A. Gessani; N.  Fini; A. Fasano; C. Caponnetto; A. Chio; E. Dalla Bella; C. Lunetta; L. Mazzini; Kalliopi Marinou Aktipi; G.  Soraru; S. De Biasi; D. Lo Tartaro; M. Pinti; A. Cossarizza

Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

RAP-ALS investigators group, RAP-ALS Investigators group, J. Mandrioli, R. D'Amico, E. Zucchi, A. Gessani, N. Fini, A. Fasano, C. Caponnetto, A. Chio, E. Dalla Bella, C. Lunetta, L. Mazzini, Kalliopi Marinou Aktipi, G. Soraru, S. De Biasi, D. Lo Tartaro, M. Pinti, A. Cossarizza

Istituti Clinici Scientifici Maugeri Spa – Società Benefit

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e11119
Journal	Medicine
Publication status	Published - 2018

Cite this

RAP-ALS investigators group, RAP-ALS Investigators group, Mandrioli, J., D'Amico, R., Zucchi, E., Gessani, A., Fini, N., Fasano, A., Caponnetto, C., Chio, A., Dalla Bella, E., Lunetta, C., Mazzini, L., Marinou Aktipi, K., Soraru, G., De Biasi, S., Lo Tartaro, D., Pinti, M., & Cossarizza, A. (2018). Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine, e11119.

RAP-ALS investigators group, RAP-ALS Investigators group, Mandrioli, J, D'Amico, R, Zucchi, E, Gessani, A, Fini, N, Fasano, A, Caponnetto, C, Chio, A, Dalla Bella, E, Lunetta, C, Mazzini, L, Marinou Aktipi, K, Soraru, G, De Biasi, S, Lo Tartaro, D, Pinti, M & Cossarizza, A 2018, 'Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)', Medicine, pp. e11119.

@article{5220af87e9da40f8b06dc3293d3afa15,

title = "Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)",

author = "{RAP-ALS investigators group} and {RAP-ALS Investigators group} and J. Mandrioli and R. D'Amico and E. Zucchi and A. Gessani and N. Fini and A. Fasano and C. Caponnetto and A. Chio and {Dalla Bella}, E. and C. Lunetta and L. Mazzini and {Marinou Aktipi}, Kalliopi and G. Soraru and {De Biasi}, S. and {Lo Tartaro}, D. and M. Pinti and A. Cossarizza",

year = "2018",

language = "English",

pages = "e11119",

journal = "Medicine (United States)",

issn = "0025-7974",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Rapamycin treatment for amyotrophic lateral sclerosis Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

AU - RAP-ALS investigators group

AU - RAP-ALS Investigators group

AU - Mandrioli, J.

AU - D'Amico, R.

AU - Zucchi, E.

AU - Gessani, A.

AU - Fini, N.

AU - Fasano, A.

AU - Caponnetto, C.

AU - Chio, A.

AU - Dalla Bella, E.

AU - Lunetta, C.

AU - Mazzini, L.

AU - Marinou Aktipi, Kalliopi

AU - Soraru, G.

AU - De Biasi, S.

AU - Lo Tartaro, D.

AU - Pinti, M.

AU - Cossarizza, A.

PY - 2018

Y1 - 2018

M3 - Article

SP - e11119

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

ER -